Rapid progression of fibrosing alveolitis and thyrotoxicosis after antithymocyte globulin therapy for aplastic anemia

Clicks: 230
ID: 115392
1970
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #30 of 85 articles by views in Annals of hematology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Antithymocyte globulin (ATG) therapy is an established form of treatment for aplastic anaemia and has also been used as prophylaxis against graft rejection of bone marrow and renal allografts. Administration of ATG preparations has been associated with many mild clinical reactions, as have other forms of immunomodulatory therapy. However, serious adverse effects appear to be rare. We report a case of rapidly progressive fibrosing alveolitis and thyrotoxicosis in relation to ATG therapy, highlighting its potential toxicity and emphasising that its administration should be undertaken by experienced physicians in specialised centres.
Reference Key
zomas1970annalsrapid Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors A. Zomas;J. C. W. Marsh;N. K. Harrison;S. L. Hyer;S. S. Nussey;G. Knee;A. G. Wilson;A. Lakhani;E. C. Gordon-Smith;A. Zomas;J. C. W. Marsh;N. K. Harrison;S. L. Hyer;S. S. Nussey;G. Knee;A. G. Wilson;A. Lakhani;E. C. Gordon-Smith;
Journal Annals of hematology
Year 1970
DOI
doi:10.1007/BF01696232
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.